PPT-TENOFOVIR ALAFENAMIDE PHARMACOKINETICS

Author : studyne | Published Date : 2020-09-29

WITH AND WITHOUT COBICISTAT IN PREGNANCY Jeremiah D Momper 1 Brookie Best 1 Jiajia Wang 2 Alice Stek 3 Tim R Cressey 4 Sandra Burchett 5 Regis Kreitchmann

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "TENOFOVIR ALAFENAMIDE PHARMACOKINETICS" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

TENOFOVIR ALAFENAMIDE PHARMACOKINETICS: Transcript


WITH AND WITHOUT COBICISTAT IN PREGNANCY Jeremiah D Momper 1 Brookie Best 1 Jiajia Wang 2 Alice Stek 3 Tim R Cressey 4 Sandra Burchett 5 Regis Kreitchmann 6 David E Shapiro. An HIV pre-exposure prophylaxis trial in Thailand: . participant adherence and study results . National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Division of HIV/AIDS Prevention. A collaborative project involving: The Bangkok Metropolitan Administration, the. based . PrEP. technologies in women : . what do we currently know?. Linda-Gail Bekker . The Desmond Tutu HIV Centre. University of Cape Town.. Expanding HIV Prevention Options for Women.. The need for a female initiated, managed and controlled prevention methodology.. John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. Albany Medical Center Hospital. NY/NJ AIDS Education and Training Center. When to Start. DHHS: Changing Criteria for Initiating ART. CD4+ Count, cells/mm. Jessica Tagerman, . PharmD. , . RPh. Pharmacokinetics & pharmacodynamics. Pharmacodynamics: What the drug does to the body. Pharmacokinetics: What the body does to the drug. pharmacodynamics. “What the drug does to the body”. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 3rd Quarter. October-December 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. A.Dravid. 1. ,A.Sadre. 2. ,S.Dhande. 1. , A.Borkar. 1. ,M.Kulkarni. 1. ,M.Dravid. 3. 1. . Ruby hall clinic, Department of HIV Medicine, . Pune. , India. 2. Ruby hall clinic, Department of Nephrology, . of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 2nd Quarter. July-September 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. Program. Improving Health. . . Promoting Wellness. QUARTERLY . SUMMARY. 1. st. Quarter. APRIL-JUNE 2017. 2017/2018 Ryan White Grant Year. COUNTY HEALTH DEPARTMENTS . BY PHARMACY CATEGORY. PUTNAM. MARION. The . use of drugs to treat psychiatric disorders is often the foundation for a successful treatment approach that can also include other types of intervention such as psychotherapy and behavior therapy. . STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine. STEAL: Study Design. Source: . Martin A, et al. . Clin. Infect . Dis. 2009;49:1591. -1601. .. Study Design: STEAL. Background. ADONE Trial. Simplification to Efavirenz-Tenofovir DF-Emtricitabine . ADONE: Study Design. Source: . Airoldi. M, et al. Patient Prefer Adherence. 2010;4:115-25.. Study Design: ADONE Study . Background. Diese Präsentation dient ausschließlich der wissenschaftlichen Information gegenüber ärztlichen Fachkreisen. . Die Präsentation enthält keine werblichen Aussagen und dient nicht zu Werbezwecken. . Tenofovir. . Disoproxil. . Fumarate. to . Tenofovir. . Alafenamide. Have Improved Renal and Bone Safety through 48 Weeks. Study GS-US-292-0112. Samir K. Gupta. 1. , Anton Pozniak. 2. , Jose Arribas.

Download Document

Here is the link to download the presentation.
"TENOFOVIR ALAFENAMIDE PHARMACOKINETICS"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents